-+ 0.00%
-+ 0.00%
-+ 0.00%

Navamedic Extends Nordic Mysimba Distribution Agreement With Azurity for Five Years

PUBT·10/20/2026 06:49:04
Navamedic Extends Nordic Mysimba Distribution Agreement With Azurity for Five Years
  • Navamedic extended its agreement with Azurity Pharmaceuticals for Nordic distribution rights to oral obesity treatment Mysimba by five years.
  • The extension takes effect April 26, 2027, on largely similar terms, with an upfront licensing fee.
  • Azurity acquired Mysimba in 2026; Navamedic has distributed the treatment in the Nordic region under an exclusive agreement since 2017.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Navamedic ASA published the original content used to generate this news brief via Cision (Ref. ID: 202610200245BITN____UKPR__EN_20261020-BIT-6748-0) on October 20, 2026, and is solely responsible for the information contained therein.